These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34803757)

  • 1. Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey.
    Evens R; Reiche S; Marek RM; Moon DU; Groß RE; Romanello A; Jalilzadeh Masah D; Scicchitano Böckheler M; Gutwinski S; Montag C; Mick I; Majić T
    Front Psychiatry; 2021; 12():732028. PubMed ID: 34803757
    [No Abstract]   [Full Text] [Related]  

  • 2. Cannabis use during the early COVID-19 pandemic: Use patterns, predictors, and subjective experiences.
    Mielau J; Reiche S; Moon DU; Groß E; Gutwinski S; Betzler F; Romanello A; Masah DJ; Scicchitano M; Marek R; Brandt L; Evens R; Mick IM; Majić T; Montag C
    Front Psychiatry; 2022; 13():1037451. PubMed ID: 36704748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers.
    Boehnke KF; Cox K; Weston C; Herberholz M; Glynos N; Kolbman N; Fields CW; Barron J; Kruger DJ
    Front Psychiatry; 2023; 14():1224551. PubMed ID: 37599880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.
    Palmer M; Maynard OM
    Harm Reduct J; 2022 Jul; 19(1):81. PubMed ID: 35871679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.
    Kuc J; Kettner H; Rosas F; Erritzoe D; Haijen E; Kaelen M; Nutt D; Carhart-Harris RL
    Psychopharmacology (Berl); 2022 May; 239(5):1425-1440. PubMed ID: 34734314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world.
    Lake S; Lucas P
    Int J Drug Policy; 2024 Aug; 130():104507. PubMed ID: 38936219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study.
    Révész D; Ona G; Rossi GN; Rocha JM; Dos Santos RG; Hallak JEC; Alcázar-Córcoles MÁ; Bouso JC
    Front Psychiatry; 2021; 12():687546. PubMed ID: 34220590
    [No Abstract]   [Full Text] [Related]  

  • 9. Predicting Responses to Psychedelics: A Prospective Study.
    Haijen ECHM; Kaelen M; Roseman L; Timmermann C; Kettner H; Russ S; Nutt D; Daws RE; Hampshire ADG; Lorenz R; Carhart-Harris RL
    Front Pharmacol; 2018; 9():897. PubMed ID: 30450045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics.
    Kruger DJ; Enghoff O; Herberholz M; Barron J; Boehnke KF
    J Psychoactive Drugs; 2023; 55(5):631-639. PubMed ID: 37078418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study.
    Barbut Siva J; Barba T; Kettner H; Kuc J; Nutt DJ; Carhart-Harris R; Erritzoe D
    J Psychopharmacol; 2024 Feb; 38(2):145-155. PubMed ID: 38281075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturalistic Psychedelic Use: A World Apart from Clinical Care.
    Glynos NG; Fields CW; Barron J; Herberholz M; Kruger DJ; Boehnke KF
    J Psychoactive Drugs; 2023; 55(4):379-388. PubMed ID: 35950817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No party, no drugs? Use of stimulants, dissociative drugs, and GHB/GBL during the early COVID-19 pandemic.
    Bendau A; Viohl L; Petzold MB; Helbig J; Reiche S; Marek R; Romanello A; Moon DU; Gross RE; Masah DJ; Gutwinski S; Mick I; Montag C; Evens R; Majić T; Betzler F
    Int J Drug Policy; 2022 Apr; 102():103582. PubMed ID: 35093679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case analysis of long-term negative psychological responses to psychedelics.
    Bremler R; Katati N; Shergill P; Erritzoe D; Carhart-Harris RL
    Sci Rep; 2023 Sep; 13(1):15998. PubMed ID: 37749109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meditation trips: A thematic analysis of the combined naturalistic use of psychedelics with meditation practices.
    Azmoodeh K; Thomas E; Kamboj SK
    Exp Clin Psychopharmacol; 2023 Jun; 31(3):756-767. PubMed ID: 36534415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ).
    Wolff M; Evens R; Mertens LJ; Schmidt C; Beck J; Rutrecht H; Cherniak AD; Gründer G; Jungaberle H
    J Psychopharmacol; 2024 May; 38(5):432-457. PubMed ID: 38742761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making "bad trips" good: How users of psychedelics narratively transform challenging trips into valuable experiences.
    Gashi L; Sandberg S; Pedersen W
    Int J Drug Policy; 2021 Jan; 87():102997. PubMed ID: 33080454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabis as entheogen: survey and interview data on the spiritual use of cannabis.
    Johnstad PG
    J Cannabis Res; 2020 Sep; 2(1):30. PubMed ID: 33526128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the subjective experience of rave party participants in Israel who consume psychedelic drugs: a qualitative inquiry.
    Milshteyn Y; Bensimon M
    Harm Reduct J; 2023 Dec; 20(1):176. PubMed ID: 38057811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.